These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15287202)

  • 1. Therapeutic approach of patients with IgA nephropathy.
    Goumenos DS; Brown CB
    Ren Fail; 2004 Mar; 26(2):171-7. PubMed ID: 15287202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of IgA nephropathy.
    Pozzi C
    J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.
    Strippoli GF; Manno C; Schena FP
    Am J Kidney Dis; 2003 Jun; 41(6):1129-39. PubMed ID: 12776264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F; Vecchio LD; Pozzi C
    Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of IgA nephropathy with chronic renal failure].
    Pozzi C
    G Ital Nefrol; 2008; 25 Suppl 44():83-7. PubMed ID: 19048591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
    Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
    Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of immunoglobulin A nephropathy.
    Schiele J; Nowack R; Julian BA; van der Woude FJ
    Ann Med Interne (Paris); 1999 Feb; 150(2):127-36. PubMed ID: 10392261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
    Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
    Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of IgA nephropathy].
    Amoroso L; De Sanctis L; Cappelli P; Di Vito R; Sirolli V; Bonomini M
    G Ital Nefrol; 2011; 28(6):622-32. PubMed ID: 22167613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin antagonists and fish oil for treating IgA nephropathy.
    Coppo R; Amore A; Peruzzi L; Mancuso D; Camilla R
    Contrib Nephrol; 2007; 157():27-36. PubMed ID: 17495434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
    J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of IgA nephropathy with renal insufficiency.
    Pozzi C; Sarcina C; Ferrario F
    J Nephrol; 2016 Aug; 29(4):551-8. PubMed ID: 26743078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IgA nephropathy].
    Alamartine E
    Rev Prat; 2003 Nov; 53(18):2023-6. PubMed ID: 15008216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
    Chen S; Yin Q; Ren S; Zhong X; Wang W; Li G; Wang L
    Sci Rep; 2018 Sep; 8(1):13662. PubMed ID: 30209279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoglobulin A nephropaty: clinical practice guidelines].
    Fayad A; Robaina Sindin J; Calvo Abeucci M; Trimarchi H; Vázquez V
    Medicina (B Aires); 2011; 71 Suppl 2():1-26. PubMed ID: 21903506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.
    Coppo R
    J Nephrol; 2017 Jun; 30(3):339-346. PubMed ID: 27815919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IgA nephropathy: from predicting progression to treatment].
    Rauta V; Grönhagen-Riska C
    Duodecim; 2006; 122(2):215-22. PubMed ID: 16509071
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoglobulin A nephropathy: fish oils and beyond.
    Feehally J
    Curr Opin Nephrol Hypertens; 1996 Sep; 5(5):442-6. PubMed ID: 8937814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.